Eli Lilly & Co. LLY said Friday a late-stage trial of a treatment for a type of non-small cell lung cancer met its main goal. The Phase 3 trial dubbed Libretto-431 showed a statistically significant and clinically meaningful improvement in progression-free survival for Retevmo versus platinum-based chemotherapy in treating adults with rearranged during transfection (RET) fusion-positive advanced or metastatic non-small cell lung cancer. “The labeling for Retevmo contains warnings and precautions for hepatotoxicity (evidence of liver dysfunction), interstitial lung disease (ILD)/pneumonitis, hypertension, QT interval…
